With this in mind perhaps, Dexcom has launched its Stelo device ... for its products having mass-market appeal, in order to keep the share price buoyant. I have fallen into this trap myself ...

Q4 2024 Management View Kevin Sayer, CEO, highlighted that Q4 2024 organic revenue growth was 8%, contributing to a full-year organic growth of 12%, aligned with guidance. The company ended 2024 with ...

Dexcom CEO Kevin Sayer shared new data on the ... Most users signed up for subscriptions versus a one-time order. Stelo brought in $22 million in revenue in 2024, nearly $10 million less than ...

the continued rollout of Stelo, further international expansion, and overall market dynamics. For fiscal 2024, DexCom (DXCM) estimates unaudited revenue of approximately $4.032B ($4.02B estimate ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

In March 2024, the Food and Drug Administration cleared Dexcom’s Stelo as the first over-the ... Additionally, eating foods in a specific order—like eating the lettuce and tomato first ...

Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.

Dexcom’s focus on expanding continuous glucose monitoring access, rolling out new products like the Stelo, and its plans ... on the stock with a $100.00 price target. TipRanks tracks over ...

The flagship G7 and DexCom ONE+ platforms continued to drive adoption internationally, with launches in key regions such as France, Australia and Japan bolstering growth. Early success with the newly ...